Advance vaccine platforms for universal influenza vaccine
Ended Awarded Last action
- Contract number
- 75N91018F00067
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $27,056,808
Award facts
- Opportunity
-
- N01CO5240180 Solicitation number
- Operations and Technical Support for the Frederick National Laboratory for Cancer Research (FLNCR), a Federally Funded Research and Development Center (FFRDC) Award Notice · Posted Apr 27, 2015
- Contract value 100% obligated
- $27,056,808.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- National Institute of Allergy and Infectious Diseases National Institutes of Health, Department of Health and Human Services
- NAICS code
- 561210 Facilities Support Services
- Set-aside
- No set-aside
- Competition
- Not Competed Only One Source
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $803,056 | |
| Exercise an Option | $7,584,780 | |
| Supplemental Agreement for work within scope | $6,623,484 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $2,591,547 | |
| Original award | $9,453,941 |
About this award
The Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a Cost-Plus-Fixed-Fee delivery order contract to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc., for the "ADVANCE VACCINE PLATFORMS FOR UNIVERSAL INFLUENZA VACCINE" program. The $27,056,808.00 contract, awarded on September 30, 2018, has a completion date of September 29, 2023 and is not set aside for any specific business type. Leidos Biomedical Research is a provider of research, development, and production services to federal agencies, with a focus on supporting biomedical research programs at the NIH. This award continues Leidos Biomedical's work in areas like influenza, COVID-19, and other infectious disease research, which it has supported through past prime and subcontracts with the NIH and its various institutes.
Quick answers
Who was awarded contract 75N91018F00067?
75N91018F00067 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 30, 2018.
How much is contract 75N91018F00067 worth?
The government has obligated $27,056,808 on 75N91018F00067.
Which agency awarded contract 75N91018F00067?
National Cancer Institute (National Institutes of Health) awarded 75N91018F00067, with funding from National Institute of Allergy and Infectious Diseases (National Institutes of Health).
Is contract 75N91018F00067 an order under another contract?
Yes. 75N91018F00067 is a delivery order under HHSN261201500003I, an indefinite delivery contract.
Was contract 75N91018F00067 competed?
The extent of competition for 75N91018F00067 was not competed.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award